Form 4: Ionis Pharmaceuticals Executive Receives Stock Grants

An Ionis Pharmaceuticals executive, Kyle Jenne, received grants of performance and restricted stock units.

Summary

• Kyle Jenne, an Executive Vice President at Ionis Pharmaceuticals, received a grant of 18,700 Performance Restricted Stock Units (PRSUs) and 28,050 Restricted Stock Units (RSUs) on January 15, 2025.
• The PRSUs vest based on the company's total shareholder return compared to a peer group over a three-year period, with a maximum of 200% of the target number of units vesting.
• The RSUs vest in four equal annual installments, and each unit represents a contingent right to receive one share of Ionis common stock or its cash equivalent.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The grants of PRSUs and RSUs align executive compensation with company performance and shareholder value.
• The vesting schedule of the RSUs encourages long-term commitment from the executive.

Risks

• The actual number of PRSUs that will vest is not guaranteed and depends on the company's performance relative to its peers.
• The value of the stock units is subject to market fluctuations.

Future Outlook

The vesting of the PRSUs is contingent on the company's performance over the next three years, while the RSUs will vest annually over the next four years.

Industry Context

Stock grants are a common form of executive compensation in the pharmaceutical industry, aligning management interests with shareholder value and incentivizing long-term performance.

Comparison to Industry Standards

• Stock-based compensation is a standard practice in the biotech and pharmaceutical industry, with companies like Biogen, Gilead Sciences, and Amgen also using similar equity incentive plans.
• The vesting schedules and performance metrics used by Ionis are comparable to those used by its peers, although the specific details of the performance metrics may vary.

Stakeholder Impact

• The stock grants may positively impact shareholder value if the company performs well, leading to the vesting of the PRSUs.
• The grants incentivize the executive to work towards the long-term success of the company.

Key Dates

Keywords

stock grants, restricted stock units, performance restricted stock units, executive compensation, Ionis Pharmaceuticals, equity incentive plan, vesting